KYMR.NASDAQKymera Therapeutics, INC

Form 4: Kymera Therapeutics CFO Bruce Jacobs Reports Stock Option Exercise and Common Stock Transaction

Sentiment:

SEC Form 4 Filing

📋All filings for Kymera Therapeutics, INC
🔒Login to Follow

Chief Financial Officer of Kymera Therapeutics, Bruce N. Jacobs, reports exercising stock options and a transaction involving common stock on January 10, 2025.

Summary

  • Bruce N. Jacobs, the Chief Financial Officer of Kymera Therapeutics, reported a transaction on January 10, 2025.
  • Jacobs exercised stock options to acquire 10,000 shares of common stock at a price of $2.08 per share.
  • Following the reported transaction, Jacobs beneficially owns 178,921 shares of common stock directly.
  • Jacobs also owns 94,899 derivative securities (stock options).

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing. It simply reports transactions and doesn't inherently indicate positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions and is a standard practice for publicly traded companies. It provides transparency into the trading activities of company executives.

Stakeholder Impact

  • The transaction provides transparency to shareholders regarding insider trading activity.

Key Dates

DateDescription
July 1, 2020Twenty-five percent (25%) of the shares underlying the stock option vested.
December 1, 2024367 shares acquired under the Registrant's employee stock purchase plan.
January 10, 2025Date of stock option exercise and common stock transaction.
January 13, 2025Date of signature for the Form 4 filing.
August 28, 2029Expiration date of the stock options.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.